Expression of Multidrug Resistance-Related Proteins p-Glycoproteinglutathione-s-Transferases, Topoisomerase-II and Lung Resistance Protein in Primary Gastric Cardiac Adenocarcinoma

REFERENCES

• Ito H., Clancy T. E., Osteen R. T., Swanson R. S., Bueno R., Sugarbaker D. J., Ashley S. W., Zinner M. J., Whang E. E. Adenocarcinoma of the Gastric Cardia: What Is the Optimal Surgical Approach?. J Am Coll Surg 2004; 199: 880–886
   PubMed Web of Science ®Google Scholar
• Siewert J. R., Feith M., Werner M., Stein H. J. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000; 232: 353–361
   PubMed Web of Science ®Google Scholar
• de Manzoni G., Pedrazzani C., Pasini F., Di Leo A., Durante E., Castaldini G., Cordiano C. Results of surgical treatment of adenocarcinoma of the gastric cardia. Ann Thorac Surg 2002; 73: 1035–1040
   PubMed Web of Science ®Google Scholar
• Balon J. M., Triboulet J. P. Surgical management of and long-term survival after adenocarcinoma of the cardia. Br J Surg 2002; 89: 1156–1163
   PubMed Web of Science ®Google Scholar
• Peer D., Margalit R. Fluoxetine and reversal of multidrug resistance. Cancer Letters 2006; 237: 180–187
   PubMed Web of Science ®Google Scholar
• Triller N., Korosec P., Kern I., Kosnik M., Debeljak A. Multidrug resistance in small cell lung cancer: Expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer 2006; 54: 235–240
   PubMed Web of Science ®Google Scholar
• Lavie Y., Liscovitch M. Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences. Glycoconj J 2000; 17: 253–259
   PubMed Web of Science ®Google Scholar
• Lavie Y., Fiucci G., Liscovitch M. Upregulation of caveolin in multidrug resistant cancer cells: functional implications. Adv Drug Delivery Rev 2001; 49: 317–323
   PubMed Web of Science ®Google Scholar
• Litman T., Druley T. E., Stein W. D., Bates S. E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001; 58: 931–959
   PubMed Web of Science ®Google Scholar
• Leonard G. D., Fojo T., Bates S. E. The role of ABCtransporters in clinical practice. Oncologist 2003; 8: 411–424
   PubMed Web of Science ®Google Scholar
• Ambudkar S. V., Kimchi-Sarfaty C., Sauna Z. E., Gottesman M. M. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22: 7468–7485
   PubMed Web of Science ®Google Scholar
• Fojo T., Bates S. Strategies for reversing drug resistance. Oncogene 2003; 22: 7512–7523
   PubMed Web of Science ®Google Scholar
• Filipits M. Mechanisms of cancer: multidrug resistance. Drug Discovery Today: Disease Mechanisms 2004; 1: 229–234
   Google Scholar
• Borst P., Evers R., Kool M., Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295–1302
   PubMed Web of Science ®Google Scholar
• Gottesman M. M., Fojo T., Bates S. E. Multidrug resistance in cancer: role of ATPdependent transporters. Nat Rev Cancer 2002; 2: 48–58
   PubMed Web of Science ®Google Scholar
• Kickhoefer V. A., Rajavel K. S., Scheffer G. L., Dalton W. S., Scheper R. J., Rome L. H. Vaults are up-regulated in multidrug resistant cancer cell lines. J Biol Chem 1998; 273: 8971–8974
   PubMed Web of Science ®Google Scholar
• Cerfa E., Gaspera R., Rychnovskyb S., Changc X., Buysea F., Ruysschaert J. M. Multidrug resistance protein 1 is not associated to detergent-resistant membranes. Biochem Biophys Res Commun 2007; 355: 1025–1030
   PubMed Web of Science ®Google Scholar
• Callaghana R., Fordb R. C., Kerrc I. D. The translocation mechanism of P-glycoprotein. FEBS Letters 2006; 580: 1056–1063
   PubMed Web of Science ®Google Scholar
• Sisodiya S. M., Martinian L., Scheffer G. L., van der Valk P., Scheper R. J., Harding B. N., Thom M. Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies. Neuropathol Appl Neurobiol 2006; 32: 51–63
   PubMed Web of Science ®Google Scholar
• Tanaka P. Y., Calore E. E. P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients. Pathol Res Pract 2007; 203: 1–7
   PubMed Web of Science ®Google Scholar
• Leith C. P., Kopecky K. J., Chen I. M., Eijdems L., Slovak M. L., McConnell T. S., et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukaemia: a Southwest Oncology Group study. Blood 1999; 94: 1086–1099
   PubMed Web of Science ®Google Scholar
• Soh Y., Gotoy S., Kitajima M., Moriyama S., Kotera K., Nakayamaz T., Nakajimax H., Kondoy T., Ishimaru T. Nuclear Localisation of Glutathione S-transferase π is an Evaluation Factor for Drug Resistance in Gynaecological Cancers. Clin Oncol 2005; 17: 264–270
   Web of Science ®Google Scholar
• Gate L., Majumdar R. S., Lunk A., Tew K. D. Influence of Glutathione S-Transferase pi and p53 Expression on Tumor Frequency and Spectrum in Mice. Int J Cancer 2005; 113: 29–35
   PubMed Web of Science ®Google Scholar
• Gate L., Tew K. D. Glutathione S-transferases as emerging therapeutic targets. Expert Opin Ther Targets 2001; 5: 477–489
   PubMedGoogle Scholar
• Goto S., Kamada K., Soh Y., Ihara Y., Kondo T., et al. Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs. Jpn J Cancer Res 2002; 93: 1047–1056
   PubMedGoogle Scholar
• Goto S., Ihara Y., Urata Y., Izumi S., Abe K., Koji T., Kondo T. Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase pi. FASEB J 2001; 15: 2702–271
   PubMed Web of Science ®Google Scholar
• Dingemans A. M. C., van Ark-Otte J., Span S., Scagliotti G. V., van der Valk P., Postmus P. E., Giaccone G. Topoisomerase II_ and other drug resistance markers in advanced non-small cell lung cancer. Lung Cancer 2001; 32: 117–128
   PubMed Web of Science ®Google Scholar
• Nielsen D., Maare C., Skovsgaard T. Cellular resistance to anthracyclines. Gen Pharmacol 1996; 27: 251–255
   PubMedGoogle Scholar
• Giaccone G. DNA topoisomerases and topoisomerase inhibitors. Pathol Biol. 1994; 42: 346–352
   PubMed Web of Science ®Google Scholar
• Gotlieb W. H., Goldberg I., Weisz B., Davidson B., Novikov I., Kopolovic J., Ben-Baruch G. Topoisomerase II Immunostaining as a Prognostic Marker for Survival in Ovarian Cancer. Gynecologic Oncology 2001; 82: 99–104
   PubMed Web of Science ®Google Scholar
• Scheper R. J., Broxterman H. J., Scheffer G. L., Kaaijk P., Dalton W. S., van Heijningen T. H., van Kalken C. K., Slovak M. L., de Vries E. G., van der Valk P. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein mediated multidrug resistance. Cancer Res 1993; 53: 1475–1479
   PubMed Web of Science ®Google Scholar
• Izquierdo M. A., Shoemaker R. H., Flens M. J., Scheffer G. L., Wu L., Prather T. R., Scheper R. J. Overlapping phenotypes of multidrug resistance amongpanels of human cancer-cell lines. Int J Cancer 1996; 65: 230–237
   PubMed Web of Science ®Google Scholar
• Berger W., Elbling L., Micksche M. Expression of the major vault protein LRP in human non-small cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer 2000; 88: 293–300
   PubMed Web of Science ®Google Scholar
• Laureysa G., Benoita Y. Philippéb, Jan. Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. European Journal of Cancer 2006; 423: 295–309
   Google Scholar
• Izquierdo M. A., Van der Zee A. G. J., Vermorken J. B., Van der Valk P., Belien J. A. M., Giaccone G., Scheffer G. L., Flens M. J., Pinedo H. M., Kenemans P., Meijer C. J. L. M., De Vries E. G. E., Scheper R. J. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995; 87: 1230–1232
   PubMed Web of Science ®Google Scholar
• Lagarde S. M., ten Kate F. J. W., Richel D. J., Offerhaus G. J. A., van Lanschot J. J. B. Molecular, Prognostic Factors in Adenocarcinoma of the Esophagus and Gastroesophageal Junction. Ann Surg Oncol 2006; 14: 977–991
   PubMed Web of Science ®Google Scholar